ARTICLE | Clinical News
BL-8040: Phase I/II started
December 14, 2015 8:00 AM UTC
BioLine began an open-label, U.S. Phase I/II trial to evaluate subcutaneous BL-8040 plus standard immunotherapy in up to 25 patients. Patients will receive 0.75 mg/kg BL-8040 on days 1-10, then on the...